Mr. Mike Withrow reports

AREV LIFE SCIENCES GLOBAL CORP. ANNOUNCES FILING OF APPLICATION FOR MANAGEMENT CEASE TRADE ORDER

Arev Life Sciences Global Corp. has been granted a management cease trade order as it was not able to meet the filing deadline of April 30, 2023, to file its audited annual financial statements and accompanying management's discussion and analysis (MD&A), and related chief executive officer and chief financial officer certificates, for the year ended Dec. 31, 2022, as required under applicable Canadian securities laws.

In connection with the company's inability to file the annual filings on time, the company has applied for and have been granted a management cease trade order (MCTO) under National Policy 12-203, Management Cease Trade Orders, and by the British Columbia Securities Commission. The company applied for an MCTO due to the unexpected closing of the company's auditor, Harbourside CPA LLP, and the difficulty of finding an auditor for the company having a year-end of Dec. 31, and the company was unable to progress with its audit, within the time frame to file on or before April 30, 2023. This impacted the company's ability to complete its audited annual financial statements and has consequently caused a delay in completion of the annual filings.

The company has engaged BF Borgers CPA as its auditing firm to prepare the audited financial statements of the company, which are expected to be completed on or before June 15, 2023. This measure has been taken in compliance with regulatory requirements and with the objective of upholding the company's financial reporting transparency and precision.

The company expects to file the annual filings as soon as they are available, but in any event on or before June 15, 2023 (two-month period contemplated by NP 12-203).

Until the company files the annual filings, it will comply with the alternative information guidelines set out in NP 12-203. The guidelines, among other things, require the company to issue biweekly default status reports, in the form of news releases, for so long as the annual filings have not been filed.

During the MCTO, the general investing public will continue to be able to trade in the company's common shares listed on the Canadian Securities Exchange. However, the company's chief executive officer and chief financial officer, and such other directors, officers and persons as determined by the applicable regulatory authorities, will not be able to trade in the company's shares, nor will the company be able to, directly or indirectly, issue securities to or acquire securities from an insider or employee of the company until such time as the annual filings and all continuous disclosure requirements have been filed by the company, and the MCTO has been lifted.

About Arev Life Sciences Global Corp.

The company is a fully integrated enterprise with competencies in: (1) extraction of compounds for consumption and topical use; (2) clinical nutrition; and (3) a technology platform called Medicine Merchant. The company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The company's business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The company continues in the product development and precommercialization stage.

Arev is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. Arev is a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO).

We seek Safe Harbor.